Roche UK Confirms Submission of their Application for an Early Access to Medicines Scheme (EAMS)
05 May 2020 / Posted in: Treatments & Research
Roche took this planned step on 4th May. It usually takes approximately 90 days to hear the outcome.
Roche’s Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants who have SMA Type 1
28 April 2020 / Posted in: Treatments & Research
Roche has shared an update on part 2 of the FIREFISH clinical trial. FIREFISH Part 2 is a pivotal, global study evaluating risdiplam in 41 infants aged 1 to 7 months old with symptomatic SMA Type 1.
Disability Rights UK's Petition To Increase Disability Benefits
28 April 2020 / Posted in: Information, Support
In response to the COVID-19 pandemic, the Government announced a temporary emergency increase of £20 a week for both Universal Credit and Working Tax Credits. This petition is calling on the Government to immediately extend this emergency increase to all benefits.
FAQs re Access to Roche’s risdiplam Compassionate Use Programme (CUP) in the UK
24 April 2020 / Posted in: Treatments & Research
The following FAQs have been checked for accuracy with Roche. We hope they will help to clarify further how their COVID-19 response measures affect pre-approval access to risdiplam in the UK, including practical aspects of the programme.
Impact of COVID-19 on SMA UK
22 April 2020 / Posted in: Information, Support
We are still here for you and this will remain our key focus. We have, though, had to make some difficult decisions and cuts to survive our drop in income.
Roche Updates SMA UK about their COVID-19 Response Measures and Pre-Approval Access to Risdiplam
17 April 2020 / Posted in: Treatments & Research
Following our enquiry, we received a community update today. This covers: maintaining risdiplam supply; ongoing risdiplam clinical trials and support services; Compassionate Use for risdiplam.
Extension of the New Drug Application (NDA) Timetable for Risdiplam in the USA
14 April 2020 / Posted in: Treatments & Research
Roche has advised the SMA Community that the US FDA recently informed them that due to the volume of additional data submitted by Roche, they will need a three-month review extension of the New Drug Application (NDA) of risdiplam. Roche, therefore, expects a decision from the FDA by 24th August 2020.
Easter Bank Holiday
08 April 2020 / Posted in: Information, Support
SMA UK staff won’t be working over the Easter Weekend - so will finish at the end of Thursday 9th April and will be back working at 9am on Tuesday 14th. Find out about where to find information, including re COVID-19, during this time.
Continued Advocacy re: Access to Nusinersen For All Those Who Have SMA Type 3
07 April 2020 / Posted in: Treatments & Research
Please be assured that SMA UK, MDUK and TreatSMA are still actively working on this and continue to ask NICE and NHS England to address the concerns we have at the earliest possible time.
NICE’s Scoping of Risdiplam Treatment Delayed due to COVID-19
07 April 2020 / Posted in: Treatments & Research
NICE has announced that as it has to prioritise work that is either therapeutically critical or relates to addressing COVID-19 diagnostic or therapeutic interventions, it will not go ahead with this stage of the appraisal process at this time.
